Inmune Stock News

INmune Bio has multiple potential catalysts ahead including the go-ahead to start Phase 2 trials with XPro in the US. The company will soon file an IND for its immunotherapy candidate INKmune in a sol

The company has two clinical stage drugs with promising early results enjoying multiple use cases and facing multi-billion dollar market opportunities. XPro looks especially promising in mild cognitiv

INmune Bio, Inc. (NASDAQ:INMB ) Q3 2022 Results Conference Call November 2, 2022 4:30 PM ET Company Participants David Moss - Chief Financial Officer Dr. RJ Tesi - Chief Executive Officer Dr. CJ Barnu

Management to host conference call and webcast at 4:30 pm E T on that day

INmune Bio, Inc. (NASDAQ:INMB ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants David Moss – Co-Founder and Chief Financial Officer RJ Tesi – Co-Founder and Chief E

Increased analyst coverage over the past few weeks may lead to solid price appreciation for stocks like Malibu (MBUU), Cantaloupe (CTLP), INmune (INMB), Swedish Match (SWMAY) and GATX.

The FDA places clinical hold on INmune Bio's (INMB) IND application to begin a phase II study on the investigational TNF inhibitor, XPro1595, for Alzheimer's disease.

INmune Bio's XPro is probably the most-promising drug candidate in the history of neurodegenerative diseases. INMB's share price just dropped at an all-time low due to a US-related clinical hold for X

Shares of INmune Bio Inc. INMB, -1.09% plummeted 31.4% toward a 22-month low in premarket trading Tuesday, after the Florida-based biotechnology company said it received an email from U.S. Food and Dr

INmune Bio, Inc. (NASDAQ:INMB ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants David Moss – Co-Founder and Chief Financial Officer RJ Tesi – Chairman and Chief Execut

Management to host conference call and webcast at 4:30 pm ET on that day Management to host conference call and webcast at 4:30 pm ET on that day

INmune (INMB) doses the first patient in a phase II study with its investigational TNF inhibitor to treat Alzheimer's disease. Stock rises more than 12% post this announcement.

Data from animal models of trastuzumab-resistant MUC4 HER2+ breast cancer show that treatment with INB03 decreases MUC4 expression, reverses resistance to trastuzumab and tyrosine kinase inhibitors, a

INKmune therapy, NK cell therapy, was shown to activate NK cells that killed off >70% of NK resistant tumor cells in an in vitro assay in an MDS patient.

INmune Bio, Inc. (INMB) CEO Raymond J. Tesi on Q4 2021 Results - Earnings Call Transcript